PNAS study shows 15-PGDH inhibition preserves muscle during GLP-1 weight loss
PNAS study shows 15-PGDH inhibition preserves muscle during GLP-1 weight loss
X PNAS article spike; GLP-1 users seeking muscle preservation strategies
People taking GLP-1 weight-loss drugs (like Ozempic, Wegovy) are learning that the drugs can shrink muscle along with fat. New science shows a specific protein inhibitor might preserve muscle during weight loss. Users are scrambling for supplements and protocols to keep muscle while on these drugs.
GLP-1 users want the weight loss without looking skinny-fat or losing strength. This is the first time there's been a specific, science-backed answer to 'how do I keep my muscles while losing weight on these drugs' — so creators and brands are racing to explain it and sell solutions.
GLP-1 users on Google and X are actively searching for muscle-preservation science, but TikTok and Instagram engagement is still low—audience is information-hungry, not yet sold on solutions.
GLP-1 users skew affluent (out-of-pocket $300-500/mo or insured), urban (telemedicine access), and female (63-68% of prescriptions are women). Peak age is 25-34 (millennials with discretionary income + wellness consciousness) and 35-44 (higher incidence of diabetes + weight concerns). High income proxy: anyone spending $30-50/mo on supplements is already affluent relative to general population. US coastal and Sunbelt regions have highest telemedicine clinic density and GLP-1 prescription rates. UK signals secondary because NHS GLP-1 rollout is sparking same conversation.